"","Blank 1","Frequency","Blank 2","Frequency"
"36","prior",12,"                                                                                                                                                                                                                                                                                   ",34
"255","prior radiation",5,"chemotherapy with delayed toxicity extensive radiation therapy immunotherapy biologic therapy or vaccine therapy within the last 3 weeks chemotherapy regimens without delayed toxicity within the last 2 weeks preceding the first dose of study treatment                                                                                                                                                                                                                                                       ",3
"274","patients may have received prior radiation",4,"within 14 days prior to registration                                                                                                                                                                                                                                                                                   ",3
"45","ongoing radiation",3,"e . g . birth control pills ovarian hormone replacement therapy patients are eligible if these medications are discontinued prior to randomization                                                                                                                                                                                                                                                                  ",2
"51","prior systemic anti cancer",3,"immunotherapy chemotherapy investigational agent for malignancy or radiation = < 28 days before study registration no treatment with nitrosourea or mitomycin = < 42 days before study registration                                                                                                                                                                                                                                                              ",2
"107","no prior",3,"either with all or with a portion of the neoadjuvant chemotherapy regimen unless medically contraindicated                                                                                                                                                                                                                                                                    ",2
"2","patients must not receive any other anti cancer",2,"is allowed patients must not have received minimal radiation therapy = < 5 of their total marrow volume within 3 weeks prior to the initiation of study treatment otherwise patients must not have received radiation therapy > = 5 of their total marrow volume within 4 weeks prior to the initiation of study treatment patients who have received prior radiation to 50 or more of their total marrow volume will be excluded                                                                                                                                                                                                                    ",2
"6","patients must not have received any prior systemic",2,"or chemotherapy                                                                                                                                                                                                                                                                                          ",2
"27","any continued use of sex hormonal",2,"/ chemotherapy                                                                                                                                                                                                                                                                              ",2
"47","patients who have received any systemic corticosteroid",2,"are not eligible                                                                                                                                                                                                                                                                                  ",2
"48","concurrent anticancer",2,"xrt small port > = 2 weeks                                                                                                                                                                                                                                                       ",2
"61","patients may have received prior hormonal",2,"is permitted while on study                                                                                                                                                                                                                                                                                      ",1
"123","prior / concurrent",2,"cytotoxic biologic radiation or hormonal other than for replacement while on this study except for medications that are prescribed for supportive care but may potentially have an anti cancer effect i . e . megestrol acetate bisphosphonates these medications must have been started 1 month prior to enrollment on this study in addition men receiving treatment for prostate cancer will be maintained at castrate levels of testosterone by continuation of luteinizing releasing hormone agonists                                                                                                                                                                                                            ",1
"134","patients must not be planning to receive concomitant other biologic",2,"and have relapsed less than a year from their last platinum regimen regimens that are used twice for example carboplatin and paclitaxel can be counted as one if a regimen is changed during the course of treatment due to side effect profile or allergic reaction the course of therapy is counted as one regimen for example if docetaxel is substituted for paclitaxel due to a reaction during the initial course of adjuvant therapy this is considered one regimen                                                                                                                                                                                                       ",1
"189","progression on at least one prior systemic chemotherapy for advanced unresectable or metastatic disease prior adjuvant or neoadjuvant",2,"eg radiation therapy biologic agents local therapy embolization radiofrequency ablation laser are not eligible                                                                                                                                                                                                                                                                  ",1
"191","no treatment with biologic",2,"directed at the malignant tumor must be discontinued at least one week prior to registration continuation of hormone replacement therapy is permitted                                                                                                                                                                                                                             ",1
"208","no prior chemotherapy or radiation",2,"chemotherapy or other biologic therapy for lung cancer                                                                                                                                                                                                                                                                              ",1
"213","patients with her2 positive tumors must have received neoadjuvant anti her2",2,"on aall0932 patients receiving prior steroid therapy may be eligible for aall0932                                                                                                                                                                                                                                      ",1
"222","current systemic chemotherapy or radiation",2,"for their breast cancer prior to registration                                                                                                                                                                                                                                                                               ",1
"267","the subject has received radiation",2,"cytotoxic biologic radiation or hormonal other than for replacement while on this study except for medications that are prescribed for supportive care but may potentially have an anti cancer effect i . e . megestrol acetate bisphosphonates in addition men receiving treatment for prostate cancer will be maintained at castrate levels of testosterone by continuation of luteinizing releasing hormone agonists                                                                                                                                                                                                                          ",1
"288","radiation",2,"or for tumors where sorafenib based therapy would be standard therapy phase i                                                                                                                                                                                                                                                            ",1
"311","at least 6 weeks must have elapsed prior to enrollment since the patient received any prior radiation",2,"for relapse or first relapse if immunosuppressive chemotherapy contraindicated primary refractory disease or if persistent disease after first line therapy of relapse or multiply relapsed patients in remission who are at a high risk of relapse or the lymphoma is a second malignancy e . g . a richter s transformation of chronic lymphocytic leukemia cll after failing frontline therapy or group b after autologous or syngeneic stem cell transplant sct as adjuvant therapy                                                                                                                                                                                       ",1
"1","no other experimental",1,"for relapse or first relapse if immunosuppressive chemotherapy contraindicated primary refractory disease or if persistent disease after first line therapy of relapse or multiply relapsed patients in remission who are at a high risk of relapse or the lymphoma is a second malignancy e . g . a richter s transformation of cll after failing frontline therapy or group b after autologous or syngeneic sct as adjuvant therapy                                                                                                                                                                                             ",1
"3","patients must have received < 3 lines of prior",1,"for one month prior to entry in this study                                                                                                                                                                                                                                                                             ",1
"4","patients that have been previously treated with chemotherapy for hepatoblastoma or other hepatoblastoma directed",1,"for at least 1 week prior to entry in this study including rituximab                                                                                                                                                                                                                                                                          ",1
"5","recovery from effects of recent surgery radiotherapy or chemotherapy patients must be entered within 8 weeks after surgery performed for either 1 initial diagnosis staging and / or cytoreduction or 2 if done management of recurrent disease in a chemonaive patient any hormonal",1,"chemotherapy biotherapy or hormonal therapy for this cancer prior to surgery i . e . any neoadjuvant chemotherapy or endocrine therapy is not allowed patients who undergo surgical resection with breast conservation and then are treated with adjuvant systemic therapy are eligible to enroll prior to the start of radiotherapy                                                                                                                                                                                                                                         ",1
"7","with the exception of steroid pretreatment defined below or the administration of intrathecal cytarabine patients must not have received any prior cytotoxic chemotherapy for either the current diagnosis of b all or b lly or for any cancer diagnosed prior to initiation of protocol",1,"hrt = < 4 weeks prior to registration this includes the use of vaginal estrogen therapy                                                                                                                                                                                                                                                                          ",1
"8","patients must not have begun chemotherapy or endocrine",1,"will be allowed as long as the patient meets all other eligibility criteria                                                                                                                                                                                                                                                                      ",1
"9","patients who are able to comply with the anti emetic",1,"or within 28 days prior to initiation of first induction course for patients with prior therapy                                                                                                                                                                                                                                    ",1
"11","rcc patients only tumor progression after receiving standard / approved chemotherapy and / or targeted agent where there is no approved",1,"refractory disease persistent sites of disease after less than a partial response to frontline therapy following a minimum of 4 cycles of induction therapy and patient has never had a relapse / progression persistent disease persistent disease after achieving at least a partial response to frontline therapy after a minimum of 4 cycles of induction therapy and patient has never had a relapse / progression                                                                                                                                                                                                     ",1
"12","first line advanced hcc i . e . no prior systemic",1,"prior to start of protocol therapy                                                                                                                                                                                                                                                                             ",1
"13","procurement diagnosis of hodgkinï s or non hodgkinï s lymphoma group a with active disease in second or subsequent relapse in first relapse for indolent lymphoma after first line",1,"regimens for example from intraperitoneal to intravenous therapy for reasons other than progression will count as 1 prior therapy bevacizumab and other ï targetedï agents will count in the total number of prior regimens vaccine therapies will not count in the total of prior therapies                                                                                                                                                                                                                              ",1
"14","treatment diagnosis of hodgkinï s or non hodgkinï s lymphoma group a with active disease in second or subsequent relapse in first relapse for indolent lymphoma after first line",1,"within 7 calendar days of registration                                                                                                                                                                                                                                                                                     ",1
"15","treatment patients should have been off other investigational",1,"if a test that is repeated after registration and prior to therapy is outside the limits for eligibility it must be rechecked within 48 hours prior to the start of therapy if laboratory values still fail to meet eligibility criteria the patient may not receive protocol therapy                                                                                                                                                                                                                                ",1
"16","treatment patients should have been off conventional",1,"i . e . definitive surgery and radiation therapy and adjuvant chemotherapy for breast cancer prior to registration in addition any prior local therapy and adjuvant chemotherapy should be completed prior to participant completion of baseline patient reported outcomes pro instruments i . e . health assessment questionnaire haq promis physical function functional assessment of cancer therapy fact breast and endocrine symptoms es etc . and collection of optional blood for banking for future research                                                                                                                                                                                                             ",1
"17","treatment including radiation",1,"is not allowed                                                                                                                                                                                                                                                                  ",1
"18","patients on hormone replacement",1,"with exemestane letrozole or anastrozole as preoperative / adjuvant therapy or for prevention of breast cancer prior tamoxifen is allowed                                                                                                                                                                                                                                                                   ",1
"19","no concomitant anti cancer chemotherapy or other systemic drugs palliative radiation",1,"chemotherapy immunotherapy or therapy with biologic agent including immunotoxins immunoconjugates antisense peptide receptor antagonists interferons interleukins tumor infiltrating lymphocytes til lymphokine activated killer lak or gene therapy or hormonal therapy for their brain tumor glucocorticoid therapy is allowed                                                                                                                                                                                                                                         ",1
"20","patients must have newly diagnosed active multiple myeloma mm except where otherwise indicated below that assessment is required within 14 days all tests for establishing baseline disease status must be completed within 28 days prior to registration for patients with no prior",1,"and concomitant temozolomide at least 28 days but no more than 49 days prior to starting treatment on this study patients must have received at least 80 of planned temozolomide and radiation therapy with no grade 3 or grade 4 toxicity except lymphopenia attributed to the temozolomide arm 2 patients may not have received any other prior chemotherapy immunotherapy or therapy with biologic agent including immunotoxins immunoconjugates antisense peptide receptor antagonists interferons interleukins til lak or gene therapy or hormonal therapy for their brain tumor prior gliadel wafers are allowed glucocorticoid therapy is allowed                                                                                                                                                                                    ",1
"21","patients must have at least one of the following recurrent / progressive disease at any time prior to enrollment regardless of response to frontline",1,"regimens                                                                                                                                                                                                                                                                                     ",1
"22","a minimum of 6 weeks must have elapsed after 131i mibg",1,"either with all or with a portion of the neoadjuvant chemotherapy regimen therapy must be food and drug administration fda approved targeted anti her2 therapy but additional therapies are allowed as are non trastuzumab regimens if administered in the context of an institutional review board irb approved clinical trial                                                                                                                                                                                                                         ",1
"23","all cytokines or hematopoietic growth factors must be discontinued a minimum of 7 days prior to protocol",1,"nsclc post at least two lines of therapy or granulosa cell ovarian cancer post at least one line of therapy patients must have measurable disease                                                                                                                                                                                                                                                         ",1
"24","more than 4 prior chemotherapy regimens note repeat use of regimens count as 1 prior regimen switching front line",1,"eligible subjects must have had 1 line of systemic cytotoxic treatment this may be adjuvant therapy with documented progression within 12 months of completion or 1 line of cytotoxic therapy for metastatic disease note eligible patients are allowed up to 2 lines of systemic cytotoxic treatment of which only 1 line is allowed for metastatic disease the acceptance of progression within 12 months of adjuvant is part inclusion to not require patient to re challenge with chemotherapy chemo if they progressed soon after adjuvant therapy prior hormonal therapy for metastatic / recurrent disease is also allowed prior targeted therapy not directed against cmet or vascular endothelial growth factor vegf pathways is allowed                                                                                                                                                                             ",1
"25","patients must start",1,"patients must be off anti androgen therapy for at least 30 days                                                                                                                                                                                                                                                                              ",1
"26","laboratory values must be no older than seven 7 days prior to the start of",1,"or history of clinically significant autoimmune disease as defined by previously requiring immunosuppressive therapy                                                                                                                                                                                                                                                                          ",1
"28","patients must have completed planned local",1,"must have been completed at least 21 days prior to enrollment no concomitant anti lymphoma therapy including systemic corticosteroids for the purpose of treatment of lymphoma are allowed topical steroids are allowed                                                                                                                                                                                                                                                            ",1
"29","note concomitant treatment with ongoing trastuzumab herceptin or other targeted / biologic agents is allowed concomitant treatment with any other type of chemotherapy or hormonal",1,"chemotherapy immunotherapy biologic therapy or combination regimens all adverse events associated with prior treatment must have resolved to = < grade 1 prior to registration                                                                                                                                                                                                                                                               ",1
"30","patients must not have received prior ai",1,"chemotherapy biotherapy hormonal therapy or investigational agent prior to study entry                                                                                                                                                                                                                                                                            ",1
"31","patients going on arm 1 or combination dose cohort must not have received prior radiation",1,"with anti angiogenic agents is permitted                                                                                                                                                                                                                                                                                       ",1
"32","patients going on arm 2 must have received planned treatment with radiation",1,"with belinostat                                                                                                                                                                                                                                                                                           ",1
"33","patients may have an unlimited number of prior",1,"chemotherapy hormonal therapy directed at the tumor immunotherapy or biologic therapy                                                                                                                                                                                                                                                                                 ",1
"34","patients with her 2 positive tumors must have received neoadjuvant trastuzumab or trastuzumab pertuzumab or other approved anti her 2",1,"for prostate cancer will not need to discontinue this therapy to be eligible however patients with prostate cancer will need to have metastatic prostate cancer that has progressed despite hormonal therapy castrate testosterone levels occur within hours after castration and within 2 to 3 weeks of a luteinizing hormone releasing hormone agonist the current standard is to continue androgen suppression despite progressive disease                                                                                                                                                                                                                      ",1
"35","phase ii histologically confirmed colorectal adenocarcinoma post at least two lines of",1,"within 3 weeks prior to the start of therapy with the exception of physiological replacement doses of cortisone acetate or equivalent                                                                                                                                                                                                                                                                  ",1
"37","no ongoing anti androgen",1,"including other investigational agents with the exception of hormone therapy for prostate cancer                                                                                                                                                                                                                                                                               ",1
"38","active as defined by requiring immunosuppressive",1,"for multiple myeloma where a line of therapy for myeloma is defined as 1 or more planned cycles of single agent or combination therapy as well as a planned series of treatment regimens administered in a sequential manner e . g . lenalidomide bortezomib and dexamethasone induction therapy for 4 cycles followed by autologous stem cell transplantation and then lenalidomide maintenance therapy would be considered 1 line of prior therapy a new line of therapy begins when a planned therapy is modified to include other treatment agents alone or in combination as a result of disease progression disease relapse or treatment related toxicity e . g . a patient is progressing in the face of lenalidomide maintenance therapy and has bortezomib and dexamethasone added into their regimen a new line of therapy also begins when a planned treatment free interval is interrupted by the need to start treatment due to disease relapse / progression e . g . a patient with relapsed myeloma achieves a partial response after a planned 8 cycles of cyclophosphamide bortezomib and dexamethasone enjoys an 8 month period off therapy but then experiences disease progression requiring re initiation of therapy                                                                                       ",1
"39","relapsed or refractory after at least 1 front line",1,"prior treatment with interferon in the adjuvant setting is allowed though prior treatment with ipilimumab in the adjuvant setting is not prior radiation therapy is allowed though must have included no more than 3000 centigray cgy to fields including substantial marrow                                                                                                                                                                                                     ",1
"40","all prior",1,"is allowed if given < 3 months prior to initiation of this protocol therapy a diagnostic study using < 10 mci of radioactive iodine rai is not considered radioactive iodine therapy no external beam radiation therapy < 4 weeks prior to initiation of therapy on this protocol no chemotherapy or targeted therapy e . g . tyrosine kinase inhibitor is allowed < 4 weeks prior to the initiation of therapy                                                                                                                                                                                                            ",1
"41","patients may have received prior systemic",1,"was completed > = 6 months prior to study enrollment                                                                                                                                                                                                                                                                             ",1
"42","treatment for this cancer including surgery radiation",1,"requirements at least one prior therapy using an agent with the potential for prolonged remission generally includes interleukin 2 checkpoint blocking antibodies or adoptive cell therapy at least 4 weeks from last dose of prior chemotherapy or immunomodulator therapy with resolution of the acute toxicities for patients coming off molecularly targeted therapy at least 2 weeks since last dose and recovery from laboratory and constitutional toxicities patients must meet entry eligibility criteria at least 2 weeks from completion of prior radiation therapy with no residual radiation toxicities at least 4 weeks from last dose of prior investigational therapy with recovery to meet baseline eligibility criteria not receiving any current anticancer therapy note any patient whose tumors carry a b raf proto oncogene serine / threonine kinase braf v600 mutation should either be excluded or may be included after experiencing progression following treatment with braf inhibitor regimen or if they consent and agree to forgo food and drug administration fda approved therapies that increase median survival                                                                                                                        ",1
"46","patients on bisphosphonates for any cancer or on hormone",1,"within 30 days prior to initiation of protocol therapy                                                                                                                                                                                                                                                                                    ",1
"49","1 prior line of systemic",1,"chemotherapy with delayed toxicity extensive radiation therapy immunotherapy biologic therapy or vaccine therapy within the last 3 weeks prior to first dose of dabrafenib and / or trametinib chemotherapy regimens without delayed toxicity within the last 2 weeks preceding the first dose of study treatment biologics will not be allowed within 30 days prior to or during navitoclax administration                                                                                                                                                                                                            ",1
"50","study participants must have completed any prior treatment at least 3 weeks prior to treatment on this protocol prior treatments may have included chemotherapy however may not have included braf or mek inhibitors or immunotherapies interleukin 2 ipilimumab anti programmed death pd 1 antibodies etc . excluding vaccine",1,"interleukin il 2 interferon immunosuppressive agents or chronic use of systemic corticosteroids used in the management of cancer or non cancer related illnesses                                                                                                                                                                                                                                                              ",1
"52","no recent treatment for thyroid cancer as defined as no radioactive iodine",1,"for treatment of endometrial carcinoma all hormonal therapy must be discontinued at least one week prior to the first date of study therapy                                                                                                                                                                                                                                                                 ",1
"54","prior administration of anthracyclines is acceptable if",1,"e . g . interferons                                                                                                                                                                                                                                                                                   ",1
"55","current use of statin",1,"radiotherapy unless palliative doses which must be discussed with study principal investigator surgery anti angiogenic therapy or interferon > = 28 days before study entry                                                                                                                                                                                                                                                            ",1
"57","chronic systemic or regular inhaled corticosteroid use within 7 days prior to initiation of protocol",1,"chemotherapy with delayed toxicity extensive radiation therapy immunotherapy biologic therapy or vaccine therapy within the last 3 weeks prior to day 1 of cycle 1 patients are permitted to be on dabrafenib and trametinib standard of care at start of therapy without wash out period prior to day 1 of cycle 1 dosing will change to protocol determined dose levels on day 1 of cycle 1                                                                                                                                                                                                                     ",1
"58","immunosuppressive",1,"to index lesions > = 28 days prior to registration on this protocol if there has been documented progression by recist criteria prior radiation therapy to the non index lesions is allowed if > = 28 days prior to registration on this protocol prior rai therapy is allowed if > = 90 days prior to registration on this protocol and evidence of progression as defined above has been documented in the interim a diagnostic study using < 10 mci of rai is not considered rai therapy prior chemotherapy is allowed if > = 28 days prior to registration on this protocol patient may have received any number of prior lines of therapy no prior use of sorafenib or an mammalian target of rapamycin mtor including phosphoinositide 3 kinase pi3k or protein kinase b akt inhibitor for the treatment of thyroid cancer                                                                                                                                         ",1
"59","patients who have had immunotherapy chemotherapy or radiotherapy within 14 days prior to the first dose of navitoclax or prior systemic anti cancer",1,"for any stage of disease stages i iv and must have progressed during or following their most recent line of therapy for patients whose prior systemic therapy was for stage i iii disease only i . e . patient has not received any treatment for stage iv or recurrent disease the prior systemic therapy must have been a platinum based chemotherapy regimen and disease progression on the platinum based chemotherapy must have occurred within one year from the last date that patient received that therapy for patients whose prior therapy was for stage iv or recurrent disease the patient must have received at least one line of a platinum based chemotherapy regimen or checkpoint inhibitor therapy e . g . nivolumab or pembrolizumab pre screening prior to progression on current treatment to be eligible for pre screening current treatment must be for stage iv or recurrent disease and patient must have received at least one dose of the current regimen patients must have previously received or currently be receiving a platinum based chemotherapy regimen or checkpoint inhibitor therapy e . g . nivolumab or pembrolizumab patients on first line platinum based treatment are eligible upon receiving cycle 1 day 1 infusion note patients will not receive their sub study assignment until they progress and the s1400 notice of progression is submitted",1
"60","patients who have received any of the following concomitant",1,"for cancer treatment concurrent use of hormones for non cancer related conditions e . g . insulin for diabetes and hormone replacement therapy is acceptable                                                                                                                                                                                                                                                       ",1
"62","concurrent systemic corticosteroids cytokines and immunomodulatory",1,"patients must have recurred or progressed following at least one platinum based chemotherapy regimen patients may have received an unlimited number of prior therapy regimens patients may not have received all of the five choices in the ï standard therapyï arm any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration any other prior therapy directed at the malignant tumor including chemotherapy and radiation therapy must be discontinued at least 4 weeks prior to registration any investigational agent must be discontinued at least 28 days prior to registration                                                                                                                                                                                             ",1
"63","all patients must have completed any prior chemotherapy targeted",1,"at least 14 days since the completion of cytotoxic therapy with the exception of hydroxyurea which is permitted up to 24 hours prior to the start of protocol therapy or maintenance chemotherapy or intrathecal chemotherapy methotrexate strongly preferred administered at the time of the required diagnostic lumbar puncture to establish baseline cns status                                                                                                                                                                                                                                        ",1
"64","patients who received prior systemic anti cancer",1,"= < 6 months except as a radiosensitizer                                                                                                                                                                                                                                                                                   ",1
"65","there is no limitation in the number of prior lines of",1,"with or without prior endocrine therapy for advanced disease note in either setting treatment with any prior endocrine therapy must be completed > = 2 weeks prior to course 1 day 1 c1d1 of study treatment with the exception of exemestane which is permitted in the advanced disease setting within = < 4 weeks immediately prior to c1d1 prior adjuvant exemestane is allowed if the disease free interval is > = 12 months from the discontinuation of exemestane prior faslodex everolimus palbociclib or other cyclin dependent kinase cdk inhibitor e . g . ribociclib abemaciclib use are allowed and must have been completed > = 2 weeks prior to c1d1 failure to adhere to this washout guideline will result in a protocol violation                                                                                                                         ",1
"66","prior treatment patients may have received prior radiation",1,"patients with acute lymphoblastic leukemia may receive intrathecal therapy                                                                                                                                                                                                                                                        ",1
"67","patients must either be eligible to be screened at progression on prior treatment or to be pre screened prior to progression on current treatment patients will either consent to the screening consent or the pre screening consent not both these criteria are screening at progression on prior treatment to be eligible for screening at progression patients must have received at least one line of systemic",1,"is allowed < 6 months prior to initiation of therapy on this protocol a diagnostic study using < 10 millicurie mci of rai is not considered rai therapy no external beam radiation therapy < 4 weeks prior to initiation of therapy on this protocol previous treatment with radiation for any indication is allowed if the investigator judges that the previous radiation does not significantly compromise patient safety on this protocol no chemotherapy or targeted therapy e . g . tyrosine kinase inhibitor is allowed < 4 weeks prior to the initiation of therapy on this protocol                                                                                                                                                                                  ",1
"68","patients must have progressed in the opinion of the treating investigator following the most recent line of",1,"radiation therapy major surgery other investigational or anti cancer therapy that is considered disease directed                                                                                                                                                                                                                                                                     ",1
"69","patients must not be planning to receive any concurrent chemotherapy immunotherapy biologic or hormonal",1,"other than corticosteroids e . g . cyclosporine a tacrolimus etc . within 28 days of the first dose of study drug                                                                                                                                                                                                                                                                     ",1
"71","no waiting period for patients who relapse while receiving standard maintenance",1,"chemotherapy anti endocrine therapy anti her2 or other standard targeted therapy for metastatic breast cancer must be given or planned to be given if given before study entry it cannot have exceeded a duration of 12 months at the time of registration note sequencing of ablative therapy surgery or sbrt relative to systemic therapy for patients randomized to arm 2 is at the discretion of the treating physician                                                                                                                                                                                                        ",1
"72","cytotoxic",1,"therapy i . e . within 6 months of last platinum therapy patients who received greater than two prior platinum containing regimens will not be eligible                                                                                                                                                                                                                                                            ",1
"73","no prior taxane",1,"or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment                                                                                                                                                                                                                                                                  ",1
"74","patients must meet at least one of the following criteria disease progression any time after non steroidal aromatase inhibitor ai use in the advanced disease setting relapse while on or within = < 12 months of end of adjuvant non steroidal ai",1,"is allowed however it should be noted that lumbar puncture and intrathecal therapy at initial diagnosis of apl is not recommended                                                                                                                                                                                                                                                           ",1
"75","patients who are currently receiving other anti cancer agents are not eligible except leukemia patients receiving hydroxyurea which may be continued until 24 hours prior to start of protocol",1,"for advanced or metastatic disease including chemotherapy or egfr tyrosine kinase inhibitor therapy including gefitinib erlotinib afatinib or any experimental egfr tyrosine kinase inhibitors tki agents prior chemotherapy for non metastatic disease i . e . adjuvant therapy or concurrent chemo radiotherapy is allowed as long as > = 12 months has passed since completion of therapy adjuvant egfr directed therapy is not allowed local therapy i . e . palliative radiotherapy is allowed as long as a period of 7 days has passed since the last dose was received and the patient has recovered from any associated toxicity at the time of registration                                                                                                                                                                             ",1
"76","no recent treatment for thyroid cancer as defined as no prior rai",1,"consolidation biologic / targeted non cytotoxic agents or extended therapy maintenance / consolidation administered after surgical or non surgical assessment patients are allowed to have received but are not required to have received one to two cytotoxic regimens for management of recurrent or persistent disease for the purposes of this study poly adenosine diphosphate adp ribose polymerase parp inhibitors given for recurrent or progressive disease will be considered cytotoxic parp inhibitors given as maintenance therapy in continuation with management of primary disease will not be considered as a separate cytotoxic regimen if two cytotoxic regimens had been received for management of recurrent or persistent disease one of these regimens would have had to contain either a platinum or a taxane agent                                                                                                                          ",1
"77","at least 2 weeks have passed since prior chemotherapy biological",1,"for brain metastasis including radiosurgery and surgical resection patients must have completed prior therapy by at least 14 days prior to step 2 for surgical resection and 7 days for radiosurgery                                                                                                                                                                                                                                                          ",1
"78","concurrent systemic immunosuppressant",1,"radiotherapy except palliative radiation therapy of 30 gray gy or less or major surgery must have been completed > = 4 weeks prior to start of treatment all adverse events due to prior therapy have resolved to a grade 1 or better except alopecia and lymphopenia by start of treatment palliative radiation therapy must have been completed at least 2 weeks prior to start of treatment the radiotherapy must not be to a lesion that is included as measurable disease note prostate cancer patients may continue their luteinizing hormone releasing hormone lhrh agonist note patients may receive non protocol treatment after biopsy if clinically indicated until they receive notification of results however lack of response must be documented prior to registration to step 1 new non protocol treatment will not be permitted as intervening therapy after registration to step 0 the decision to stop the intervening non protocol treatment will be left up to the treating physician if patient has an amoi however patients will need to be off such therapy for at least 4 weeks before receiving any match protocol treatment note for patients entering the study via a designated outside laboratory no intervening systemic non protocol treatment is permitted after step 0 registration all other eligibility requirements still apply to these patients including the washouts for prior therapy noted above in this section the time restrictions outlined and the eligibility criteria for the intended subprotocol                                               ",1
"79","patients must be registered within 365 days of the initial metastatic breast cancer diagnosis first line standard systemic",1,"are ineligible                                                                                                                                                                                                                                                                            ",1
"80","ovarian cancer patients must be resistant to platinum",1,"transarterial embolization radiofrequency ablation or cryoablation treatment must be completed at least 28 days prior to initiation of study therapy radiation therapy is also allowed and must be completed at least 28 days prior to initiation of study therapy lesions treated via radiation or liver directed therapy may not be used as target lesions unless they demonstrate growth over a minimum of 3 months on subsequent imaging                                                                                                                                                                               ",1
"81","has a diagnosis of immunodeficiency or is receiving systemic steroid",1,"with belinostat or azd1775                                                                                                                                                                                                                                                                                       ",1
"83","patients may receive up to a maximum of 5 days of pre treatment with atra prior to administration of protocol",1,"for sarcoma including adjuvant systemic therapy                                                                                                                                                                                                                                                                                   ",1
"84","treatment with hydroxyurea corticosteroids any route and intrathecal cytarabine prior to beginning protocol directed",1,"or any anti leukemic therapy are not eligible for this protocol with the exception of cytarabine for the treatment of tmd                                                                                                                                                                                                                                                                  ",1
"85","patients must not have received any prior systemic anticancer",1,"patients = < 30 days from the last dose of cytarabine used for treatment of tmd                                                                                                                                                                                                                                                                             ",1
"86","patients are allowed to have received up to three prior cytotoxic regimens for treatment of their epithelial ovarian fallopian tube or primary peritoneal cancer they must have had one prior platinum based chemotherapeutic regimen for management of primary disease possibly including intra peritoneal",1,"with biologic agent including immunotoxins immunoconjugates antisense peptide receptor antagonists interferons interleukins tumor infiltrating lymphocytes til lymphokine activated killer lak or gene therapy or hormonal therapy for their brain tumor prior gliadel wafers are allowed glucocorticoid therapy is allowed                                                                                                                                                                                                                            ",1
"87","no planned concomitant non protocol directed anti cancer",1,"such as everolimus or palbociclib nor her2 directed therapy in addition to endocrine therapy                                                                                                                                                                                                                                                                       ",1
"88","patients may have had prior",1,"or patient is currently receiving or has received adjuvant endocrine therapy in the past and adjuvant endocrine therapy was initiated > = 2 years prior to diagnosis of metastatic disease note patients who developed metastatic disease while still receiving adjuvant endocrine therapy must have a planned change in the type of endocrine agent used for subsequent metastatic disease treatment patient is not receiving blocking adjuvant therapy such as toremifene or tamoxifen or patient is receiving blocking adjuvant therapy but will stop this therapy a minimum of 60 days prior to fes pet / ct while still complying with the study timeline                                                                                                                                                                               ",1
"89","concurrent neoplasia requiring cytotoxic",1,"such as chemotherapy or radiation therapy or anti tumor experimental therapy for pancreatic cancer                                                                                                                                                                                                                                                                               ",1
"90","any prior",1,"at the time of enrollment                                                                                                                                                                                                                                                                                  ",1
"92","exclusion criteria for stratum c patients who are receiving any other anti cancer or investigational drug",1,"patients who have declined first line therapy or for whom first line therapy would be clinically inappropriate will be considered eligible for the trial                                                                                                                                                                                                                                                           ",1
"93","the study will be limited to patients who are chemotherapy naive patients may have received prior systemic or liver directed local therapies for advanced uveal melanoma as long as those treatments do not involve chemotherapy this includes but is not limited to immunotherapy targeted",1,"prior chemotherapy must have included a first line platinum based regimen with or without intravenous consolidation chemotherapy patients may have received an unlimited number of platinum based therapies in the recurrent setting patients may have received up to 1 non platinum based line of therapy in the recurrent setting prior hormonal therapy will not be considered to count as this non platinum based line patients may not have had a prior anti angiogenic agent in the recurrent setting prior use of bevacizumab in the upfront or upfront maintenance setting is allowed patients may not have previously received a poly adenosine diphosphate adp ribose polymerase parp inhibitor prior hormonal based therapy for ovarian primary peritoneal or fallopian tube cancer is acceptable                                                                                                                                                                     ",1
"94","history of prior",1,"no more than 1 prior non platinum based therapy in the platinum resistant / refractory setting hormonal therapies used as single agents i . e . tamoxifen aromatase inhibitors will not count towards this line limit                                                                                                                                                                                                                                                 ",1
"95","> = 1 prior systemic",1,"with a bisphosphonate or denosumab unless it has been started more than 4 weeks prior to the first dose of the study regimen patients who are already enrolled in this study can initiate bone modifying therapy after the first set of re staging scans > = 8 weeks from cycle 1 day 1                                                                                                                                                                                                                                    ",1
"96","children who have previously received chemotherapy radiation",1,"with mtor inhibitors except for rapalog treatment as part of graft versus host gvh prophylaxis or treatment                                                                                                                                                                                                                                                                           ",1
"98","patientsï post operative treatment must have included at least 80 of standard radiation and concomitant temozolomide patients may not have received any other prior chemotherapy immunotherapy or",1,"must have stopped within 1 month prior to enrollment                                                                                                                                                                                                                                                                                  ",1
"99","patient must not be planning to receive molecular targeted",1,"chemotherapy targeted therapy or any investigational therapy for pancreatic cancer                                                                                                                                                                                                                                                                            ",1
"100","patient is not now and never has received adjuvant endocrine",1,"within 2 weeks prior to registration or plan for systemic therapy within the first 8 weeks after study registration                                                                                                                                                                                                                                                                         ",1
"102","patients who are receiving other cancer directed",1,"multi agent chemotherapy but responds to salvage therapy i . e . chemosensitive disease timeline 8 months prior to enrollment                                                                                                                                                                                                                                                            ",1
"103","patients must have completed at least 1 prior line of systemic",1,"ripe or equivalent for active tb patients with tb immune reconstitution syndrome iris requiring corticosteroids note patients who are receiving therapy beyond month one of initial therapy with no evidence of tb iris requiring corticosteroid therapy or those receiving treatment for latent tuberculosis inh or alternative may be eligible after discussion with the protocol p . i .                                                                                                                                                                                                                          ",1
"105","no more than 3 prior treatment regimens including primary",1,"no line limit but no more than 1 prior regimens in the platinum resistant setting no prior treatment targeting the atr / checkpoint kinase 1 chk1 pathway and no prior gemcitabine as single agent hormonal therapies immunotherapy and antiangiogenic therapies as single agents do not count as lines poly adenosine diphosphate adp ribose polymerases parp inhibitors count as a line of therapy unless given in the maintenance setting parp inhibitors given as maintenance after platinum therapy do not count as a line of therapy prior carboplatin / gemcitabine is allowed provided that there was no disease progression within 12 months after completion of the carboplatin / gemcitabine regimen subjects may begin protocol treatment at least 4 weeks or 5 half lives whichever is shorter after their last dose of chemotherapy or hormonal therapy assuming they are otherwise eligible                                                                                                                                                   ",1
"106","recent initiation of bone modifying",1,"for metastatic disease prior adjuvant or neoadjuvant chemotherapy does not count as a prior line of therapy as long as completion of the adjuvant or neoadjuvant therapy was more than 1 year prior to patient enrollment                                                                                                                                                                                                                                                    ",1
"108","concurrent anti cancer",1,"in the form of tamoxifen or an aromatase inhibitor alone or in combination with ovarian suppression note for patients with er and pr staining in less than 5 of cells hormonal therapy for at least 5 years is strongly recommended but not required hormonal therapy can be initiated prior to or during protocol therapy                                                                                                                                                                                                                   ",1
"109","be receiving any form of treatment for cancer with the exception of hormonal or biologic",1,"criteria patients must have documented progressive cancer following at least one but no more than two prior regimens of systemic therapy for lung cancer one of which must have been platinum based combination chemotherapy treatment with an immune therapy or targeted therapy for advanced disease will be considered a separate regimen and will count toward the prior regimens maintenance therapy will not be counted as a separate regimen adjuvant chemotherapy or chemotherapy administered as part of concurrent chemotherapy and radiation therapy for the treatment of lung cancer will not count as a prior regimen of systemic therapy as long as recurrence of patientï s lung cancer occurred more than 12 months after the last day of chemotherapy                                                                                                                                                                      ",1
"110","the adjuvant endocrine",1,"within 4 weeks prior to the start of therapy or 12 weeks if given to treat graft versus host disease gvhd with the exception of physiological replacement doses of cortisone acetate or equivalent                                                                                                                                                                                                                                                      ",1
"111","patients must not have received prior surgery radiation",1,"including but not limited to vaccines antibodies tyrosine kinase inhibitors or hormonal therapy for management of their epithelial ovarian fallopian tube or peritoneal primary cancer                                                                                                                                                                                                                                                               ",1
"112","no systemic",1,"e . g . chemotherapy radiation therapy biologic therapy immunotherapy hormonal therapy investigational therapy                                                                                                                                                                                                                                                                              ",1
"113","prior treatment with blinatumomab or cd directed car t cell",1,"or any other form of immunosuppressive therapy within 7 days prior to the first dose of study therapy the use of physiologic doses of corticosteroids may be approved after consultation with the study principal investigator pi                                                                                                                                                                                                                                                   ",1
"114","any number of prior lines of",1,"for this cancer before randomization                                                                                                                                                                                                                                                                                       ",1
"115","biopsy proven advanced stage follicular lymphoma that have failed at least two lines of",1,"e . g . chemotherapy or targeted therapy for other invasive cancer within 5 years before randomization for the purposes of this study hormonal therapy is not considered chemotherapy                                                                                                                                                                                                                                                                ",1
"116","at least 4 weeks from end of monoclonal antibody",1,"as determined by the treating physician is allowed the last dose of chemotherapy or radiation therapy must be at least 30 days prior to study registration concurrent hormonal therapy will be allowed                                                                                                                                                                                                                                                     ",1
"117","at least 2 weeks from end of targeted",1,"chemotherapy or combination regimens in the 180 days just prior to registration prior biologic therapy immunotherapy and hormonal therapy are allowed                                                                                                                                                                                                                                        ",1
"118","active systemic immunosuppressive",1,"for treatment of endometrial carcinoma all hormonal therapy must be discontinued at least 4 weeks prior to registration                                                                                                                                                                                                                                                                      ",1
"119","active tuberculosis tb patients who are undergoing first month of",1,"hormonal therapy chemotherapy surgery or other cancer therapy while on study                                                                                                                                                                                                                                                                          ",1
"121","no limit on prior lines of",1,"radiation therapy hormonal therapy other chemotherapy anti cancer surgery or other anti cancer therapy while on this protocol                                                                                                                                                                                                                                                                  ",1
"122","patients with hormone receptor positive breast cancer as defined above must plan to receive at least 5 years of adjuvant hormonal",1,"or lymphoma which has progressed after all food and drug administration fda approved therapy                                                                                                                                                                                                                                                                 ",1
"125","patients who have received any targeted",1,"for prostate cancer are eligible for this therapy                                                                                                                                                                                                                                                                          ",1
"127","diagnosis of immunodeficiency or receiving systemic steroid",1,"with topoisomerase i inhibitors is allowed                                                                                                                                                                                                                                                                                       ",1
"128","any antineoplastic",1,"chemotherapy hormonal therapy directed at the tumor immunotherapy or biologic therapy including investigational agents for their disease                                                                                                                                                                                                                                                                           ",1
"129","antineoplastic",1,"in the form of surgery any local / regional disease recurrence should be technically treatable with sbrt or hypofractionated radiation after induction systemic therapy .                                                                                                                                                                                                                                                         ",1
"130","prior adjuvant treatment with chemotherapy and / or endocrine",1,".                                                                                                                                                                                                                                                                          ",1
"131","patients must be registered prior to or on the same day as their first cycle of chemotherapy for their current disease and stage or disease setting patient must not have had any systemic",1,"non cytotoxic non immunotherapy based systemic therapy for nsclc in the first line setting . such designations would include but not be limited to treatments targeting egfr mutant positive or alk positive nsclc in the first line setting .                                                                                                                                                                                                                                                    ",1
"133","patients must not be planning to receive concomitant biologic",1,". patients with pleural effusions that have become too small for thoracentesis at the time of registration would be permitted on study indicating a significant response to first line systemic therapy .                                                                                                                                                                                                                                                 ",1
"135","patients must have histologically documented metastatic solid tumors which have progressed after one line of",1,"is excluded .                                                                                                                                                                                                                                                                                         ",1
"136","patients receiving denosumab or bisphosphonates for any cancer or undergoing androgen deprivation",1,"including radiation excluding rankl inhibitors and bisphosphonates in event patient recently received any other systemic anti cancer therapy patient must be off therapy at least 7 days prior to registration and any therapy induced toxicity must have recovered to = < grade 1 except alopecia and = < grade 2 neuropathy which are allowed any planned radiation therapy must be completed before enrollment onto s1609                                                                                                                                                                                                             ",1
"139","if primary disease in the thoracic cavity was previously treated with local",1,"the date should be calculated from the last administered dose of platinum therapy                                                                                                                                                                                                                                                                ",1
"140","patients must be registered within 35 days of administration of the last dose of first line / induction systemic",1,"hormonal therapies e . g . tamoxifen aromatase inhibitors will not count toward the prior regimen limit                                                                                                                                                                                                                                                                       ",1
"141","patients receiving targeted",1,"e . g . chemotherapy targeted therapy within 3 weeks prior to entering the study                                                                                                                                                                                                                                                                         ",1
"142","patients with malignant pleural effusions that do not resolve after first line systemic",1,"e . g . cediranib for platinum resistant recurrence note prior bevacizumab in initial therapy and / or platinum sensitive recurrent setting is allowed                                                                                                                                                                                                                                                           ",1
"143","prior bevacizumab",1,"directed at nf1 related tumor manifestations                                                                                                                                                                                                                                                                              ",1
"144","patients must not currently be receiving any other investigational agents or any other systemic anti cancer",1,"such as tipifarnib pirfenidone peg intron sorafenib imatinib or other targeted therapies are eligible for enrollment at least 4 weeks must have elapsed since receiving medical therapy directed at the plexiform neurofibromas pn and patients who received previous gist directed therapy must either demonstrate progression as defined by recist or be unable to tolerate their previous therapy patients who received prior medical therapy for their pn must have recovered from the acute toxic effects of all prior therapy to = < grade 1 before entering this study                                                                                                                                                                                              ",1
"145","recurrent platinum resistant ovarian cancer defined as progression within < 6 months from completion of platinum based",1,"chemotherapy hormonal therapy immunotherapy or biologic therapy directed at the tumor those patients with a plexiform neurofibroma requiring treatment will be eligible                                                                                                                                                                                                                                                                      ",1
"146","1 2 prior regimens including primary",1,"radiation therapy intravesical chemotherapy surgery or other therapy while on this protocol                                                                                                                                                                                                                                                                        ",1
"147","patients who have had systemic anticancer",1,"including act for 28 days prior to study administration of atezolizumab                                                                                                                                                                                                                                                                              ",1
"148","patients with prior treatment with bevacizumab or any other anti vascular",1,"for this disease                                                                                                                                                                                                                                                                                         ",1
"149","at least 4 weeks must have elapsed since receiving medical",1,"biologic hormonal therapy for cancer treatment                                                                                                                                                                                                                                                                                    ",1
"150","patients who have received previous investigational agents or biologic",1,"is allowed however this study excludes 1 patients whose relapse occurred on hma based therapy immediately prior to this study and 2 patients who experience disease progression see definition below while receiving hma based therapy within the last 12 weeks prior to treatment start on study disease progression is defined as either 1 patients with mds who have evidence of initial progression to aml defined by the presence of > = 20 blasts in peripheral blood or bone marrow while receiving hma based therapy within the last 12 weeks prior to treatment start on study or 2 patients with aml who have evidence of progressive disease according to european leukemia net eln 2017 criteria e . g . > = 50 increase in marrow blasts over baseline or > = 50 increase in peripheral blasts to > = 25000 / mcL > = 25 000 / ul in absence of differentiation syndrome while receiving hma based therapy within the last 12 weeks prior to treatment start on study note patients who relapse post transplant who received hma treatment prior to transplant are eligible for study                                                                                                 ",1
"153","no prior other anti cancer",1,"except lhrh agonist or antagonist immunotherapy radioisotope therapy or rt within 21 days prior to start of the study agents                                                                                                                                                                                                                                                                    ",1
"155","any concurrent chemotherapy immune",1,"with ssa is permitted a stable dose at least 2 months prior to study start and must continue on the stable dose while receiving study treatment ssa is not considered as systemic treatment                                                                                                                                                                                                                                                          ",1
"156","prior hypomethylating agent hma",1,"and must meet the following minimum duration from prior anti cancer directed therapy prior to enrollment if after the required timeframe the numerical eligibility criteria are met e . g . blood count criteria the patient is considered to have recovered adequately                                                                                                                                                                                                                                     ",1
"157","patients who have had chemotherapy hormonal",1,"e . g . radiolabeled antibody 131 iodine metaiodobenzylguanidine 131i mibg > = 42 days after systemically administered radiopharmaceutical therapy                                                                                                                                                                                                                                                                         ",1
"158","prior or concurrent",1,"chemotherapy immunotherapy biologic or targeted therapy or radiation therapy for the current colon cancer except for one cycle of mfolfox6                                                                                                                                                                                                                                                                       ",1
"159","patients must have fully recovered from the acute toxic effects of all prior anti cancer",1,"is not counted as a systemic chemotherapeutic regimen for management of recurrent persistent or metastatic carcinoma of the cervix adjuvant therapy includes cisplatin given concurrent with primary radiation therapy ccrt and adjuvant chemotherapy given following the completion of concurrent chemotherapy and radiation therapy e . g . paclitaxel and carboplatin for up to 4 cycles                                                                                                                                               ",1
"160","radiopharmaceutical",1,"and intrathecal chemotherapy                                                                                                                                                                                                                                                                ",1
"161","not currently receiving anticoagulation",1,"hormonal therapy other chemotherapy surgery or other anti cancer therapy except radiation therapy while receiving treatment on this protocol however patients receiving extended adjuvant endocrine therapy for an earlier er positive breast cancer treated with curative intent and without recurrence for at least 5 years may continue with their endocrine therapy                                                                                                                                                                                                                                 ",1
"162","no prior medical",1,"radiation therapy hormonal therapy chemotherapy surgery or other therapy while on this protocol palliative radiation therapy or surgery can be considered for symptomatic non target lesions after discussions with the study team                                                                                                                                                                                                                                                     ",1
"163","patients must have had one prior systemic chemotherapeutic regimen for management of recurrent persistent or metastatic carcinoma of the cervix e . g . paclitaxel / cisplatin paclitaxel / cisplatin / bevacizumab at least one which must have contained bevacizumab note patients are allowed to receive 1 2 prior regimens for management of recurrent persistent or metastatic carcinoma of the cervix patients who have received more than two prior systemic regimens for management of recurrent persistent or metastatic carcinoma of the cervix are not eligible note prior adjuvant",1,"started after prostatectomy and prior to step 1 registration for > = 6 weeks 42 days                                                                                                                                                                                                                                                                            ",1
"164","patients who are currently receiving or plan to receive other anti cancer agents except hydroxyurea which may be continued until 24 hours prior to start of protocol",1,"consisting of at least 1 of the following surgery radiation therapy intralesional therapy topical therapy or systemic therapy                                                                                                                                                                                                   ",1
"165","patients must not be planning to receive concomitantly other biologic",1,"prior therapy with checkpoint inhibitors and / or other immunotherapy is allowed                                                                                                                                                                                                                                                                        ",1
"166","patients must not be planning to receive other biologic",1,"only are not eligible                                                                                                                                                                                                                                                                                     ",1
"167","the use of anti convulsants is allowed as long as the patient is on a stable dose with no seizure activity for at least 2 weeks prior to initiating trial",1,"rt chemotherapy immunotherapy or therapy with a biologic agent including immunotoxins immunoconjugates antisense peptide receptor antagonists interferons interleukins tumor infiltrating lymphocytes lymphokine activated killer cells or gene therapy or hormonal therapy for their brain tumor corticosteroid therapy is allowed                                                                                                                                                                                                                                                ",1
"168","androgen deprivation",1,"or immunotherapy for 2 weeks or other investigational agents for 3 weeks 4 half lives for any oral targeted agents or radiotherapy to a non brain site for 2 weeks before initiation of ipdr therapy patients who have recovered from serious common terminology criteria for adverse events ctcae grade 3 or more higher to grade 1 or less adverse events from the previous therapies are eligible prior / current / future hormonal therapy and / or bisphosphonates are permitted with no minimum interval to initiation of study therapy if indicated patients can receive palliative radiation therapy to a non brain site concurrent or immediately post study treatment with no minimum interval to initiation of study therapy                                                                                                                                                               ",1
"169","patients with non melanoma skin cancers nmsc must have advanced or refractory tumors advanced / unresectable is defined by at least 1 of the following criteria tumors 2 cm or more tumors considered unresectable tumors invading deep tissues such as muscle cartilage or bone tumors showing perineural invasion and / or tumors metastatic to loco regional lymph nodes and / or distant sites refractory is defined by persistent or recurrent tumor despite prior",1,"for patient convenience systemic chemotherapy must begin within 72 hours of this intrathecal therapy                                                                                                                                                                                                                                                                 ",1
"170","previous treatment with talimogene laherparepvec or other herpes virus based",1,"note that no minimum dose of bendamustine is required patients who additionally received any maintenance anti cd 20 antibody based therapy or consolidative radioimmunotherapy within 2 years of the last dose of the bendamustine therapy are eligible involved field or involved site radiation is not considered a line of therapy patients who previously received anthracycline based therapy are excluded examples of eligible 1st line treatment regimens note this list is not all inclusive bendamustine rituximab x 4 cycles bendamustine bortezomib rituximab x 6 cycles followed by rituximab maintenance bendamustine obinutuzumab x 3 cycles                                                                                                                                     ",1
"171","patients must be undergoing breast conserving",1,"during the 3 months before the diagnosis of endometrioid adenocarcinoma of the uterine corpus is established estrogen therapy alone is allowed                                                                                                                                                                                                                                                                ",1
"172","patients treated with neoadjuvant hormonal",1,"while on protocol treatment                                                                                                                                                                                                                                                                            ",1
"173","patients must not have received prior radiation",1,"= < 4 weeks prior to registration radiation therapy = < 4 weeks prior to registration radiation to > = 25 of bone marrow investigational therapy or any ancillary therapy considered investigational utilized for a non food and drug administration fda approved indication and in the context of a research investigation = < 4 weeks prior to registration subjects with prostate cancer will be permitted to continue hormone therapy                                                                                                                                                                                       ",1
"174","patients who have received systemic cytotoxic chemotherapy or approved oral targeted",1,"or investigational therapy = < 28 days prior to registration                                                                                                                                                                                                                                                                                ",1
"175","single dose intrathecal cytarabine is allowed prior to registration or prior to initiation of systematic",1,"= < 28 days prior to registration radiation therapy = < 28 days prior to registration investigational therapy or any ancillary therapy considered investigational utilized for a non food and drug administration fda approved indication and in the context of a research investigation = < 28 days prior to registration prior poly adenosine diphosphate adp ribose polymerase parp inhibitor therapy                                                                                                                                                                                                ",1
"176","completion of remission induction",1,"systemic chemotherapy immunotherapy or investigational drug within 21 days prior to sub study registration patients must have recovered = < grade 1 from any side effects of prior therapy patients must not have received any radiation therapy within 14 days prior to sub study registration                                                                                                                                                                                                                                         ",1
"177","patients must have either failed to achieve a complete remission or must have relapsed within 2 years after completing first line bendamustine containing chemoimmunotherapy including an anti cd20 monoclonal antibody as measured from the last dose of bendamustine relapsed patients must not have received any intervening chemotherapy patients must have received at least 3 cycles of bendamustine as first line",1,"immunotherapy biological therapy hormonal therapy or other thiazolidinediones tzds = < 21 days before study registration                                                                                                                                                                                                                                                                         ",1
"178","patients who have received prior progestin or anti estrogen",1,"is not included as prior systemic chemotherapy unless treatment occurred within the 6 months prior to study enrollment there is no limit to the number of prior lines of treatment a patient has received no treatment with biologic therapy immunotherapy chemotherapy investigational agent for malignancy or radiation = < 28 days before study registration no treatment with nitrosourea or mitomycin = < 42 days before study registration patients should have resolution of any toxic effects of prior therapy except alopecia to national cancer institute nci common terminology criteria for adverse events ctcae version 4 . 0 grade 1 or less                                                                                                                                                                        ",1
"179","patients must not be planning to require any additional form of systemic anti tumor",1,"> = 28 days prior to registration targeted therapy > = 28 days prior to registration radiation therapy > = 28 days prior to registration radiation to < 25 of bone marrow                                                                                                                                                                                                                         ",1
"180","eligibility criteria to participate in group 1 of the pilot study of the aya hears instrument note participants in group 1 will not receive protocol directed",1,"immunotherapy chemotherapy investigational agent for malignancy or radiation = < 28 days before study registration no treatment with nitrosourea or mitomycin = < 42 days before study registration for gist tyrosine kinase inhibitor can be continued for up to 3 days prior to initiation of study treatment                                                                                                                                                                                                                                           ",1
"181","patients must have had no prior systemic",1,"chemotherapy investigational agent for malignancy or radiation = < 28 days before re registration no treatment with nitrosourea or mitomycin = < 42 days before re registration                                                                                                                                                                                                                                                    ",1
"182","any of the following prior therapies chemotherapy = < 4 weeks prior to registration mitomycin c / nitrosoureas = < 6 weeks prior to registration immunotherapy = < 4 weeks prior to registration biologic",1,"and hormonal therapy at least 14 days prior to registration                                                                                                                                                                                                                                                                             ",1
"183","received treatment with radiation",1,"= < 28 days before study registration                                                                                                                                                                                                                                                                                   ",1
"184","any of the following prior therapies chemotherapy = < 28 days prior to registration mitomycin c / nitrosoureas = < 42 days prior to registration immunotherapy = < 28 days prior to registration biologic",1,"at least 14 days prior to registration any surgical procedure must have been performed at least 14 days prior to registration and radiation therapy must be completed at least 7 days prior to registration patients must have recovered from major side effects of prior therapies or procedures in the opinion of the local site investigator prior to registration                                                                                                                                                                                                                               ",1
"185","no other chemotherapy or radiation",1,"including chemotherapy biologic / targeted therapy and immunotherapy for treatment of endometrial cancer all therapy must be discontinued at least 4 weeks prior to registration any investigational agent must be discontinued at least 30 days prior to registration                                                                                                                                                                                                                                                   ",1
"186","no investigational",1,"or hormonal therapy within 14 days prior to registration patients must not have had chemotherapy targeted small molecule therapy or radiation therapy within 28 days 42 days for nitrosoureas or mitomycin c prior to registration patients must not have had an investigational agent or monoclonal antibodies except anti pd1 / l1 antibodies within 28 days prior to registration patients must have recovered from all adverse events due to prior anti cancer therapy residual toxicity = < grade 1 prior to registration with the exception of patients with = < grade 2 neuropath or = < grade 2 alopecia if patients received major surgery they must have recovered adequately from toxicity and / or complications from the intervention prior to registration                                                                                                                                                               ",1
"188","no treatment with chemotherapy radiation",1,"patients must have completed therapy at least 21 days prior to registration patients must have completed any radioimmunotherapy at least 84 days prior to registration patients must have recovered from all treatment related toxicities from these therapies prior to registration                                                                                                                                                                                                                                                 ",1
"190","any number of the following prior therapies is allowed chemotherapy > = 28 days prior to registration mitomycin c / nitrosoureas > = 42 days prior to registration immunotherapy > = 28 days prior to registration biologic",1,"failing to do all of the above will make the patient not eligible for calgb 30610                                                                                                                                                                     ",1
"192","no treatment with immunotherapy = < 21 days before re registration no treatment with biologic",1,"if administered at least 6 weeks and no more than 6 months and 2 weeks prior to enrollment and must be in complete remission consolidation therapy is defined as any chemotherapy or biological therapy used for a patient who has completed at least four courses of primary chemotherapy and had documented complete remission prior to initiation of such chemotherapy chemo or biological therapy                                                                                                                                                                                                                      ",1
"194","patients must have completed any prior radiation",1,"and / or systemic chemotherapy such therapy must have been completed at least 6 months prior to study entry and the patient has clear evidence of disease subsequent to such therapy patients must not have received neoadjuvant chemotherapy for the present recurrent disease                                                                                                                                                                                                                                             ",1
"195","no treatment with biological",1,"will be included as prior therapy note prior hormonal therapy e . g . leuprolide aromatase inhibitors tamoxifen and immunotherapy will be allowed and not included as a prior chemotherapy if the chemotherapy regimen is altered during the course due to issues with tolerability or safety the regimen will be counted as one using the same regimen at recurrence is counted as one regimen the addition of bevacizumab to a prior regimen is considered one regimen                                                                                                                                                                                               ",1
"196","no treatment with radiation",1,"age < 40 with prior and subtotal resection or biopsy i . e . anything less than gross total resection documented growth following prior surgery note patients with prior surgery cannot have received prior radiation chemotherapy or targeted therapy intractable seizures                                                                                                                                                                                                                        ",1
"197","patients must have completed systemic",1,"cr cri or ï morphologic disease free stateï                                                                                                                                                                                                                                       ",1
"198","patients may have received prior",1,"is allowed patients should only have had a biopsy of the primary tumor without an attempt at complete or partial resection patients will still be eligible if unplanned excision was attempted or accomplished as long as adequate imaging was obtained prior to surgery                                                                                                                                                                                                                                              ",1
"199","patients must not have had surgery biologic",1,"given as prophylaxis within 30 days is allowed                                                                                                                                                                                                          ",1
"200","for all forms of systemic",1,"risk group provided they meet all the criteria above for that risk group note in the lymph node positive groups at least one metastasis > = 2 . 0 mm must be present patients with micrometastases as the only nodal involvement pn1mi are eligible and will be categorized as node negative                ",1
"201","patients must not have had prior radiation",1,"eligibility for bct is determined at completion of therapy repeat mammogram / mcLtrasound us will be required at completion of neoadjuvant chemotherapy to determine eligibility for bct                                                                                                                                                                                                        ",1
"202","patients may have received one and only one cycle of chemotherapy prior to enrolling on cancer and leukemia group b calgb 30610 which must have included carboplatin or cisplatin and etoposide if a patient has had one cycle of cisplatin or carboplatin / etoposide prior to registration the patient must have had all of the prior to registration tests prior to starting their first cycle of chemotherapy additionally these patients also must have met all of the eligibility criteria prior to receiving the first cycle of chemotherapy registration to calgb 30610 must take place within 7 21 days after the start of the non protocol",1,"first episode of progressive disease during aggressive multi drug frontline therapy primary resistant / refractory disease less than partial response by inrc detected at the conclusion of at least 4 cycles of aggressive multidrug induction chemotherapy on or according to a high risk neuroblastoma protocol examples include a3973 anbl0532 anbl09p1 etc .                                                                                                                                                                                          ",1
"203","patients must have completed all primary chemotherapy and consolidation",1,"should have resolved                                                                                                                                                                                                                                                                            ",1
"204","patients may have received prior hormone",1,"prior to the start of neoadjuvant chemotherapy                                                                                                                                                                                                                                                                               ",1
"205","more than 2 prior chemotherapy regimens for the current malignancy full dose chemotherapy used in conjunction with concurrent radiation",1,"or other cancer therapies e . g . tyrosine kinase inhibitors are eligible if the other agents present a prevalence of toxicity similar to chemotherapy these therapies can be used in combination with chemotherapy as a single agent or in combination with each other chemotherapy will be defined as cytotoxic drugs in addition agents e . g . monoclonal antibodies and targeted agents that have a prevalence of grade 3 5 toxicity in older patients similar to chemotherapy > = 50 will be allowed a list of allowable agents single and in combination meeting this toxicity criteria will be available on the university of rochester cancer center urcc ncorp research base website as part of the study materials given the rapidly changing landscape of new drugs for cancer the study team led by the principal investigator pi will update the list accordingly after reviewing the toxicity profile of new therapies if the potentially eligible participant is to receive an approved drug or regimen not on the list contacting the urcc ncorp research base study team is required for approval prior to participant enrollment patients who are receiving approved cancer treatment in combination with radiation are eligible a patient may also be enrolled on a treatment trial and participate in this study if all other inclusion and exclusion criteria are met               ",1
"206","patients with codeleted low grade gliomas must also be considered ï high riskï by exhibiting one or more of the following characteristics age > = 40 and any surgical",1,"including chemotherapy used for radiation sensitization for treatment of endometrial carcinoma                                                                                                                                                                                                                                                                          ",1
"207","patients must be > = 28 days from the start of induction or re induction chemotherapy or from the start of consolidation cycle 1 if received and < 90 days following recovery from most recent treatment and they must have achieved and maintained a response to induction",1,"note kaposi sarcoma limited to the skin is not exclusionary unless requiring systemic chemotherapy                                                                                                                                                                                                                                                                             ",1
"209","participants who received any lymphoma directed chemotherapy or radiotherapy with the exception of a single dose of intrathecal chemotherapy given at the time of the diagnostic lumbar puncture spinal tap patients who received chemotherapy or radiotherapy for kaposiï s sarcoma > = 2 years prior to study enrollment are allowed as long as the prior treatment did not include doxorubicin in its non liposomal form prior exposure to liposomal doxorubicin is allowed prior exposure to intrathecal",1,"i . e . this protocol is intended as the initial treatment of first relapse                                                                                                                                                                                                                                             ",1
"210","patients must be high risk by belonging to one of the following risk groups completion of adjuvant chemotherapy and pathologically negative lymph nodes and a tumor measuring > = 2 cm in greatest diameter and an oncotype dx recurrence score > = 25 completed as standard of care or a mammaprint assay completed as standard of care in the high risk category patients with micrometastases as the only nodal involvement pn1mi are eligible and will be categorized as node negative completion of adjuvant chemotherapy and pathologically 1 3 positive lymph nodes and either an oncotype dx recurrence score > = 25 mammaprint assay in the high risk category completed as standard of care or tumor tissue with pathological grade iii following local practice if oncotype dx is done then rs must be > = 25 similarly if the mammaprint assay is performed it has to be high risk if the test is not done but the patient has grade iii disease then the patient is eligible and oncotype dx or mammaprint does not need to be performed completion of adjuvant chemotherapy and pathologically 4 or more positive lymph nodes completion of neoadjuvant chemotherapy and 1 or more positive nodes pathologically determined after chemotherapy note patients who receive both the neoadjuvant and adjuvant chemotherapy may be registered in the neoadjuvant",1,"that potentially causes bone marrow suppression that would preclude safe treatment of hsil                                                                                                                                                                                                                                                                            ",1
"211","eligible for bct based on clinical examination mammography and if standard practice at a given institution mcLtrasound and / or tomogram women who cannot be appropriately selected for bct based on these standard imaging studies and for whom additional imaging is recommended to clarify local disease extent will not be eligible for this trial for patients who have neoadjuvant",1,"on aall1231 with the exception of steroid pretreatment prednisone or methylprednisolone for = < 120 hours 5 days in the 7 days prior to initiating induction chemotherapy or for = < 336 hours 14 days in the 28 days prior to initiating induction chemotherapy prior exposure to any steroids that occurred > = 28 days before the initiation of protocol therapy does not affect eligibility the dose of prednisone or methylprednisolone does not affect eligibility intrathecal cytarabine the cns status must be determined based on a sample obtained prior to administration of any systemic or intrathecal chemotherapy except for steroid pretreatment system chemotherapy must begin with 72 hours of this it therapy or 600 cgy of chest irradiation if medically necessary pre treatment with dexamethasone in the 28 days prior to initiation of protocol therapy is not allowed with the exception of a single dose of dexamethasone use during sedation to prevent or treat airway edema inhalation steroids and topical steroids are not considered pretreatment                                                                                           ",1
"212","for the purposes of this study aggressive multidrug chemotherapy is defined as chemotherapy including 2 or more agents that must include an alkylating agent and a platinum containing compound patients must have one of the following first episode of recurrent disease following completion of aggressive multi drug frontline",1,"can in some cases consist of 2 different cisplatin based treatment combinations provided there is no disease progression between these two regimens for example a patient could have received 2 cycles of bleomycin etoposide and cisplatin bep followed by 2 cycles of cisplatin ifosfamide and etoposide vip if the switch from bep to vip was made due to pulmonary toxicity rather than disease progression this would be considered 1 line of prior therapy in addition if a patient received 4 cycles of bep and then underwent post chemotherapy resection of residual tumor with findings of residual viable non teratomatous gct and subsequently received 2 additional cycles of adjuvant chemotherapy etoposide cisplatin ep or an alternate regimen such as vip in the absence of disease progression this would also be considered 1 regimen however if any change in therapy is prompted by tumor progression including rising tumor markers this is considered to represent 2 lines of prior treatment prior treatment with carboplatin as adjuvant therapy is allowed provided patients meet other eligibility criteria e . g . the patient has also received 3 4 cycles of cisplatin based chemotherapy prior treatment with 1 2 cycles of bep or ep as adjuvant chemotherapy for early stage gct is allowed provided the patient also received 3 4 cycles of bep or ep again at relapse patients treated with 3 4 cycles of vip at relapse following 1 2 cycles of bep / ep are not eligible as this would be considered more than 1 line of prior therapy    ",1
"214","if adjuvant chemotherapy was administered chemotherapy related toxicity that may interfere with delivery of radiation",1,"regimen note patients who received preoperative therapy as part of a clinical trial may enroll note patients that were not able to complete their planned neoadjuvant chemotherapy for any reason i . e . toxicities etc . are eligible to participate as long as no further systemic standard of care therapy is planned by the treating physician                                                                                                                                                                                                              ",1
"215","no more than 8 weeks of neoadjuvant endocrine",1,"including lumpectomy or partial mastectomy                                                                                                                                               ",1
"216","evidence of an optic glioma malignant glioma malignant peripheral nerve sheath tumor or other cancer requiring treatment with chemotherapy or radiation",1,"that potentially causes bone marrow suppression that would preclude safe treatment of hsil note kaposiï s sarcoma limited to the skin is not exclusionary unless requiring systemic chemotherapy                                                                                                                                                                                                                                                             ",1
"217","plan to start a new cancer treatment regimen within 4 weeks from time of baseline registration the treatment regimen is up to the discretion of the treating oncology physician the regimen must include a chemotherapy drug or other agents that have similar prevalence of toxicity patients who will receive monoclonal antibody",1,"other than allowed in above criteria are excluded                                                                                                                                                                                                                                                                        ",1
"218","patients must not have received prior chemotherapy or targeted",1,"has been discontinued patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis or thoracic cavity within the last three years are excluded prior radiation for localized cancer of the head and neck or skin is permitted provided that it was completed more than three years prior to registration and the patient remains free of recurrent or metastatic disease                                                                                                                                                         ",1
"219","malignancy requiring systemic",1,"sclc platinum containing chemotherapy for limited or extensive stage disease                                                                                                                                                                                                              ",1
"220","participants must have received at least one line of prior systemic chemotherapy and must have experienced documented radiographic progression or intolerance on this",1,"with enzalutamide previous chemotherapy and / or other ar targeted approaches is allowed                                                                                                                                                                                                                                                                               ",1
"221","with the exception of intrathecal chemotherapy methotrexate strongly preferred cytarabine is permissible administered at the time of the required diagnostic lumbar puncture to establish baseline cns status patient has not received prior relapse directed",1,"alone patients may have breast reconstruction during protocol participation but definitive breast cancer surgery must be completed at least 21 days prior to registration concomitant biologic therapy hormonal therapy and bisphosphonates are acceptable                                                                                                                                                                                             ",1
"223","patients must not have received any cytotoxic chemotherapy for either the current diagnosis of t all t l ly or for any cancer diagnosis prior to the initiation of protocol",1,"is not included as prior systemic chemotherapy unless treatment occurred within the 6 months prior to study enrollment                                                                                                                                                                                                                                                          ",1
"224","no more than one prior line of chemotherapy for gct other than the 1 cycle of salvage chemotherapy definition of one line of chemotherapy one line of",1,"and must not have had major surgery chemotherapy radiation or biologic therapy within 2 weeks prior to beginning treatment note exceptions to this include events not considered to place the subject at unacceptable risk of participation in the opinion of the principal investigator pi e . g . alopecia                                                                                                                                                                                                                          ",1
"225","patients must have completed neoadjuvant taxane / anthracycline patients must not have received cisplatin or carboplatin or capecitabine as part of their neoadjuvant",1,"has been discontinued                                                                                                                                                                                                                                    ",1
"226","radiotherapy may be given before or after protocol treatment per standard of care guidelines when radiotherapy is planned prior to protocol treatment administration patients may be registered and screened while receiving radiation post mastectomy radiotherapy is required for all patients with the following primary tumor > = 5 cm prior to neoadjuvant chemotherapy clinically or at the time of definitive surgery or involvement of lymph nodes at the time of definitive surgery for patients with primary tumors < 5 cm or without lymph node involvement prior to neoadjuvant chemotherapy and at the time of definitive surgery provision of post mastectomy radiotherapy is at the discretion of the treating physician radiation of regional nodal basins is at the discretion of the treating radiation oncologist note breast radiotherapy whole breast or partial is required for patients who underwent breast conserving",1,"must follow the standard regimen although a dose reduction of up to 10 is permitted this treatment may be neoadjuvant or adjuvant chemotherapy patients must not be receiving or planning to receive concurrent radiation during systemic treatment                                                                                                                                                                                                                                    ",1
"228","patients who have received treatment with any other cytotoxic chemotherapy prior to beginning protocol",1,"or consolidation / maintenance therapy chemotherapy administered in conjunction with primary radiation as a radio sensitizer will be counted as a systemic chemotherapy regimen patients are allowed to receive but not required to receive up to a total of 3 lines of chemotherapy                                                                                                                                                                                                                            ",1
"229","patients who have received prior chemotherapy for any abdominal or pelvic tumor other than for the treatment of ovarian fallopian tube or primary peritoneal cancer within the last three years are excluded patients may have received prior adjuvant chemotherapy and radiotherapy for localized breast cancer provided that it was completed more than 2 years prior to registration and the patient remains free of recurrent or metastatic disease and hormonal",1,"requirements wt gist previously untreated participants are eligible pheo / pgl with germline sdh subunit mutation 131i methyl iodobenzylguanine mibg in patients with mibg avid tumors or cytotoxic chemotherapy cyclophosphamide vincristine and dacarbazine cvd or temozolomide is required prior to enrollment on this trial however patients who have refused cytotoxic chemotherapy or for whom treatment on this protocol prior to receiving cytotoxic chemotherapy is felt to be in the best interest for the patient by the local investigator will also be eligible hlrcc associated renal cell cancer previously untreated participants are eligible                                                                                                                                                                                                 ",1
"230","must have received at least one line of standard systemic treatment for locally advanced or metastatic disease setting of the respective tumor type for nsclc it is either pd 1 / pd l1 inhibitor or platinum containing chemotherapy or an egfr tyrosine kinase inhibitor or an alk inhibitor if sensitizing mutation present tnbc platinum containing chemotherapy pdac fluorouracil 5 fu gemcitabine or taxane containing chemotherapy either with or without radiation",1,"comprising of immunotherapy and / or platinum based chemotherapy a total of 4 cycles or courses and achieved stable disease or a partial response .                                                                                                                                                                                                                                                            ",1
"232","all adjuvant or neoadjuvant chemotherapy radiation and surgery completed at least 21 days prior to registration all triple negative patients must receive chemotherapy of the treating physicianï s choice er / pr patients must receive chemotherapy of the treating physicianï s choice unless oncotype dx or another genomic predictor score indicates that they are at low or intermediate risk of disease recurrence with endocrine",1,"on aall15p1                                                                                                                                                                                                                                                    ",1
"234","patients must have recovered to less than grade 1 or to baseline from toxicity of prior chemotherapy or biologic",1,"directed at their plexiform neurofibromas pn                                                                                                                                                                                                                                                              ",1
"235","patients who have received prior chemotherapy for any abdominal or pelvic tumor within the last three years are excluded patients may have received prior adjuvant chemotherapy and radiotherapy for localized breast cancer provided that it was completed more than 2 years prior to registration the patient remains free of recurrent or metastatic disease and hormonal",1,"for mcrpc a taxane chemotherapy administered for metastatic castration sensitive disease will not count unless patient develops disease progression within 12 months from the last dose chemotherapy                                                                                                                                                                                                                                                         ",1
"236","patients must be planning to receive one of the study allowed regimens as their initial treatment for their current disease myelosuppressive",1,"postmenopausal status is defined as age > = 60 years or age < 60 with any one or more of the conditions below amenorrheic for > = 1 year in the absence of chemotherapy and / or hormonal treatments luteinizing hormone and / or follicle stimulating hormone and / or estradiol levels in the post menopausal range radiation induced oophorectomy with last menses > = 1 year ago chemotherapy induced menopause with > = 1 year interval since last menses surgical sterilization bilateral oophorectomy or hysterectomy                                                                                                                                                                             ",1
"237","patients must have had at least one prior chemotherapeutic regimen for management of endometrial carcinoma initial treatment may include chemotherapy chemotherapy and radiation",1,"within 60 days prior to preregistration to step 0 no more than 300 days may have passed between the first day of induction therapy and preregistration to step 0 for patients who have completed induction therapy restaging evaluation must show status of partial pr or complete response cr post induction patients with evidence of clinical disease progression are not eligible for preregistration up to two regimens of chemotherapy are allowed as long as a continuous response was ongoing throughout therapy overall a partial response needs to have been achieved using studies at the time of diagnosis as the baseline note for example a patient who started treatment with rituximab / bendamustine and was then switched to rituximab r cyclophosphamide doxorubicin hydrochloride vincristine sulfate and prednisone chop due to insufficient response or excessive toxicity would be counted as having received 2 regimens however r chop alternating with r dexamethasone high dose cytarabine and cisplatin dhap as a planned induction regimen would count as one regimen                                                                                                                  ",1
"239","patients must have received first line / induction systemic",1,"within 120 days prior to registration to step 1 and no more than 300 days may have elapsed from the first dose of induction chemotherapy cycle 1 c1 day 1 d1 given until the last day of induction chemotherapy administered for those assigned to arms a c or d the date of transplant ï day 0ï must not be greater than 365 days after the first dose of induction chemotherapy c1d1 given patient must have received at least four 4 cycles of induction therapy up to two regimens of chemotherapy are allowed as long as a continuous response was ongoing throughout therapy note for example a patient who started treatment with rituximab / bendamustine and was then switched to r chop due to insufficient response or excessive toxicity would be counted as having received 2 regimens however r chop alternating with r dhap as a planned induction regimen would count as one regimen                                                                                                                                ",1
"240","with the exception of steroid pretreatment or the administration of intrathecal methotrexate or intrathecal cytarabine receipt of any other prior cytotoxic chemotherapy for either the current diagnosis of b all or any cancer diagnosed prior to the initiation of protocol",1,"which includes vincristine a corticosteroid pegaspargase with or without anthracycline and / or other standard cytotoxic chemotherapy                                                                                                                                                                                                                                                                       ",1
"241","since there is no standard effective chemotherapy for patients with nf1 and cutaneous neurofibromas patients may be treated on this trial without having received prior medical",1,"before or after the chemotherapy a short course of reduced dose chemotherapy concomitant with radiation for radiation sensitization is not considered to be adjuvant chemotherapy positive margins are allowed only if the surgical team of the patient deems further resection impossible                                                                                                                                                                                      ",1
"242","must have received at least two one prior line of",1,"e . g . sorafenib surgery transarterial chemoembolization tace ablation for present disease is acceptable                                                                                                                                                                                                                                                                           ",1
"243","postmenopausal or evidence of non pregnant status for fcbp as confirmed by a negative urine or serum pregnancy test within 7 days prior to the start of",1,"for the study cancer note prior chemotherapy or anti egf therapy for a different cancer is allowable                                                                                                                                                                                                                                                                       ",1
"244","patient may be receiving or have completed induction",1,"for salivary gland malignancy note that prior chemotherapy for a different cancer is allowable                                                                                                                                                                                                                                                                           ",1
"245","patients must have completed induction",1,"for the study cancer note that prior chemotherapy for a different cancer is allowable                                                                                                                                                                                                                                                                       ",1
"246","patient must have previously started induction",1,"note that prior chemotherapy for a different cancer is allowable                                                                                                                                                                                                                                                              ",1
"247","patients must have completed their final breast surgery rendering them free from disease with clear resection margins for invasive cancer and dcis within the following timelines 90 days prior to screening registration for patients not receiving post operative adjuvant chemotherapy or 270 days prior to screening registration for patients who have received post operative adjuvant chemotherapypatients who receive postoperative chemotherapy may receive radiation",1,"or chemotherapy for glioma note patients who have a history of prior low grade glioma with or without a distant history of prior surgery for that glioma but who have never received prior chemotherapy or radiation therapy for the glioma are eligible for the study                                                                                                                                                                                                                                             ",1
"249","prior chemotherapy targeted biological",1,"and a radical cystectomy if necessary by the joint agreement of the participating urologist radiation oncologist and medical oncologist                                                                                                                                                                                                                                                              ",1
"250","prior systemic chemotherapy or anti egf",1,"for hgg or dipg is permitted prior chemotherapy or radiation therapy for treatment of other malignancies is permitted                                                                                                                                                                                                                                                                       ",1
"251","prior systemic chemotherapy or radiation",1,"for nsclc                                                                                                                                                                                                                                                                                    ",1
"252","prior systemic chemotherapy or anti epidermal growth factor egf",1,"is allowed patients must not have received any radiation within 3 weeks prior to the initiation of study treatment patients may not have areas of irradiated marrow exceeding 40 of bone marrow volume                                                                                                                                                                                                                                                           ",1
"253","prior systemic chemotherapy for the study cancer if more than 4 cycles of induction chemotherapy or more than 6 months of targeted",1,"rt any site with concurrent lapatinib defined as 1 or more days on which the patient received both radiation therapy and lapatinib on the same day                                                                                                                                                                                                                                                                  ",1
"254","no previous chemotherapy or radiation",1,"according to standard of care guidelines before randomization omission of radiation therapy is not allowed in this high risk population of patients patients must be registered at least 21 days after completion of radiation therapy and must have recovered = < grade 1 from any of the effects of radiation                                                                                                                                          ",1
"256","history of prior radiation",1,"except for patients with a history of progressive disease patients whose only site s of disease have been radiated are eligible if at least one lesion meets at least one of the criteria listed in sites of disease above a minimum of 12 weeks prior to start of protocol therapy is required following large field radiation therapy i . e . total body irradiation craniospinal whole abdominal total lung > = 50 marrow space a minimum of 6 weeks must have elapsed prior to start of protocol therapy for other substantial bone marrow radiation                                                                                                                                                                              ",1
"257","patient must be considered able to tolerate systemic chemotherapy combined with pelvic radiation",1,"rt treatment must have been completed at least 30 days prior to registration                                                                                                                                                                                                                                            ",1
"259","patients must not have received prior chest radiation",1,"to symptomatic lesions is allowed provided there are no residual toxicity related to radiation and blood counts that meet the study requirements                                                                                                                                                                                                                 ",1
"261","concurrent radiation",1,"within 4 weeks = < 2 weeks for palliative radiation therapy                                                                                                                                                                                                                                                                              ",1
"263","patients must have completed either breast conserving surgery or total mastectomy with negative margins and appropriate axillary staging a negative margin is defined as no evidence of tumor or ductal carcinoma in situ dcis at the line of resection additional operative procedures may be performed to obtain clear margins patients who had breast conserving surgery must have completed whole breast radiation use of regional nodal basin radiation will be at the discretion of the investigator according to institutional guidelines patients with > = 4 positive lymph nodes must have completed breast / chest wall and nodal basin radiation",1,"rt for non target lesions however patients must not have received radiation for a minimum of 4 weeks prior to study entry at the site of any lesion that will be identified as a target lesion to measure tumor response lesions that have been previously radiated cannot be used as target lesions unless there is radiographic evidence of progression at the site following radiation or a biopsy done following radiation shows viable neuroblastoma palliative radiation is allowed to sites that will not be used to measure response during this study                                                                                                                                                                                        ",1
"264","radiation patients must not have received radiation small port for a minimum of two weeks prior to protocol",1,"for the currently diagnosed breast cancer prior to randomization                                                                                                                                                                                                                                                                                   ",1
"265","patients must have a history of stage 0 i ii or iii colon or rectal adenocarcinoma that has been treated per standard care with resection alone or in combination with radiation or chemotherapy adjuvant chemotherapy and radiation",1,"rt for any condition                                                                                                                                                                                                                                                                                     ",1
"266","step i patients must have received no more than one cycle 4 weeks or less of prior chemotherapy and no more than 160 mg of prior dexamethasone or equivalent dose of prednisone for treatment of symptomatic myeloma they should not have been exposed to lenalidomide bortezomib or carfilzomib for treatment of symptomatic myeloma prior radiation",1,"must be completed at least 30 days prior to enrollment and the patient must have recovered from all toxicity                                                                                                                                                                                                                                                                        ",1
"268","no interim time prior to study entry is required following prior radiation",1,"all adverse events associated with prior radiation therapy must have resolved to = < grade 1 prior to registration                                                                                                                                                                                                                                                                     ",1
"269","any radiation",1,"immunotherapy or bone marrow transplant for the treatment of dipg prior dexamethasone and / or surgery are allowed                                                                                                                                                                                                                                                                   ",1
"270","prior breast or thoracic radiation",1,"is initiated                                                                                                                                                                                                                                                          ",1
"271","patients must have prior histologically proven glioblastoma that is progressive or recurrent following radiation",1,"for treatment of endometrial carcinoma prior radiation therapy may have included pelvic radiation therapy extended field pelvic / para aortic radiation therapy and / or intravaginal brachytherapy all radiation therapy must be completed at least 4 weeks prior to the first date of study therapy                                                                                                                                                                                                                                           ",1
"272","no neoadjuvant radiation",1,"xrt small port at least 150 days must have elapsed if prior traumatic brain injury tbi craniospinal xrt or if > = 50 radiation of pelvis at least 42 days must have elapsed if other substantial bone marrow radiation including therapeutic doses of iobenguane mibg                                                                                                                                                                                                                                         ",1
"273","prior local radiation",1,"as defined and determined by the study oncologist besides concomitant tmz with radiation no other therapy neo adjuvant or adjuvant can be given prior to study registration including chemotherapy also including gliadel / carmustine bcnu wafers biologics immunotherapy radiation therapy the only exception is the optune device novottf 100a which may be started any time after end of radiation therapy up through the initiation of cycle 1 intent to use optune must be declared at registration for stratification                                                                                                                                                                                                      ",1
"275","patients must not have received any prior chemotherapy radiation",1,"to be used as a measurable eligibility lesion                                                                                                                                                                                                                                                                       ",1
"276","stratum 1 patients must not have received radiation",1,"and patients must have recovered from all radiation associated toxicities to no greater than grade 1 at the time of registration                                                                                                                                                                                                                                                       ",1
"277","previous steroid treatment and / or radiation treatment is not allowed unless it is for the emergent management of a mediastinal mass emergent steroid treatment and / or radiation treatment should stop once protocol",1,"to painful sites of bony disease or areas of impending fracture as long as sites of measurable or non measurable disease outside the radiation therapy port are available to follow                                                                                                                                                                                                                                ",1
"279","at least 14 days after local palliative radiation",1,"for prostate cancer any psa increase from post radiation therapy nadir or                                                                                                                                                                                                                                                                          ",1
"280","prior treatment must have completed standard radiotherapy and concomitant tmz",1,"or surgery treatment may begin > = 7 days after completion of local treatment patients with small < 2 cm and asymptomatic brain metastases are allowed and may be treated with radiation therapy and / or surgery concurrently with arm a or cycles 1 and 2 of arm b if deemed medically indicated radiation therapy should not be given concurrently with high dose carboplatin or etoposide                                                                                                                                                                                                          ",1
"281","if patients have had a potential index lesion radiated it must have progressed post radiation",1,"for bone metastasis within 2 weeks any other external radiation therapy within 4 weeks before the first dose of study treatment systemic treatment with radionuclides within 6 weeks before the first dose of study treatment subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible                                                                                                                                                                                                                                             ",1
"282","prior radiation is permitted however at least 2 weeks must have elapsed since the completion of prior radiation",1,"to the thoracic cavity or abdomen within 3 months before the first dose of study treatment or has ongoing complications or is without complete recovery and healing from prior radiation therapy to bone or brain metastasis within 3 weeks before the first dose of study treatment to any other site s within 28 days before the first dose of study treatment                                                                                                                                                                                                                            ",1
"283","prior radiotherapy must in general have been completed > = 2 weeks prior to randomization and patients must have recovered from the toxicity of the radiation note patients may receive concurrent radiation",1,"to the brain or whole brain radiation therapy prior single fraction or fractionated radiosurgery is permitted                                                                                                                                                                                                                                                                          ",1
"284","arm ii only for patients status post radiation",1,"within the last 4 weeks radiation exposure may not exceed 30 of marrow area                                                                                                                                                                                                                                                                            ",1
"285","patients must have histologically proven glioblastoma or gliosarcoma which is progressive or recurrent following radiation",1,"documentation of a bone marrow aspirate and biopsy containing < 10 clonal plasma cells prior to start of radiation therapy                                                                                                                                                                                                                                                                 ",1
"286","patients who have received any previous chemotherapy or radiation",1,"is not permitted except palliative limited field radiation therapy if all of the following criteria are met repeat imaging demonstrates no new sites of bone metastases the lesion being considered for palliative radiation is not a target lesion                                                                                                                                                                                                                                       ",1
"287","no large > = 2 cm hemorrhagic or symptomatic brain metastases until local treatment has been administered radiation",1,"is allowed but not required no limit on number of prior therapies no chemotherapy other investigational agents within 28 days of study treatment no other concurrent investigational agents or other meningioma directed therapy chemotherapy radiation while on study for patients treated with external beam radiation interstitial brachytherapy or radiosurgery an interval > = 24 weeks must have elapsed from completion of radiation therapy to registration steroid dosing stable for at least 4 days recovered to common terminology criteria for adverse events ctcae grade 1 or less toxicity from other agents with exception of alopecia and fatigue no craniotomy within 28 days of registration                                                                                                                                                                                   ",1
"290","patients who have received prior chemotherapy or radiation",1,"within 2 weeks prior to the first dose of the study regimen                                                                                                                                                                                                                                                                                ",1
"291","prior external beam radiation",1,"must not have been received within 2 weeks of study entry 4 weeks if prior nitrosourea biologic anti neoplastic agent at least 7 days since the completion of therapy with a biologic agent radiation therapy rt > = 2 weeks for local palliative radiation therapy rt small port > = 6 weeks must have elapsed if prior craniospinal rt or if > = 50 radiation of pelvis > = 6 weeks must have elapsed if other substantial bone marrow bm radiation surgery > = 2 weeks from last major surgery including pulmonary metastasectomy with the exclusion of a central line placement and core needle or small open biopsies                                                                                                                                                         ",1
"292","patients who received radiation",1,"within the last 2 60 months                                                                                                                                                                                                                                                                               ",1
"293","patients must have had their last fraction of craniospinal irradiation > = 3 months prior to enrollment other substantial bone marrow irradiation > = 6 weeks prior to enrollment local palliative radiation",1,"but must have measurable disease outside the radiation port at least 14 days must have elapsed since completion of prior radiation therapy patients must have recovered from all associated toxicities at the time of registration                                                                                                                                                                                                                                                     ",1
"294","inclusion criteria for stratum c patients must have had their last fraction of craniospinal irradiation > = 3 months prior to enrollment other substantial bone marrow irradiation > = 6 weeks prior to enrollment local palliative radiation",1,"rt > = 2 weeks for local palliative rt small port > = 6 months must have elapsed if prior craniospinal rt or if > = 50 radiation of pelvis > = 6 weeks must have elapsed if other substantial bone marrow bm radiation note patients must have received = < than 13 . 6 gray gy prior radiation to the mediastinum                                                                                                                                                                                                                               ",1
"295","for patients pre registering after the completion of radiation",1,"must receive concomitant radiotherapy radiation after mastectomy is to be administered according to pre specified institutional guidelines radiation must be completed at least 21 days prior to registration                                                                                                                                                                                                                                                            ",1
"296","for all patients radiation dose should range from 4500 cgy to 6000 cgy no treatment for this disease following radiation",1,"criteria patients may have had prior radiation therapy as long as it has not affected greater than 25 of the bone marrow and at least one measurable lesion is outside the area of prior radiation at least 7 days must have elapsed since last radiation treatment patients must have recovered from any adverse events from prior radiation therapy to = < ctcae grade 1                                                                                                                                                                                                                           ",1
"297","participants who have received any other investigational agents within the 4 weeks prior to enrollment concurrent radiation",1,"for treatment of endometrial cancer prior radiation therapy may have included pelvic radiation therapy extended field pelvic / para aortic radiation therapy intravaginal brachytherapy and / or palliative radiation therapy all radiation therapy must be completed at least 4 weeks prior to registration                                                                                                                                                                                                                                             ",1
"298","prior treatment prior medical",1,"wash out period requirements participants must be at least 4 weeks from prior surgical procedures and surgical incisions must be healed participants must have had their last fraction of external beam radiation therapy at least 4 weeks prior to enrollment participants with prior radiation therapy must be at least 4 weeks post therapy and have had progression of disease outside the radiation port participants must have had their last dose of cytotoxic chemotherapy at least 28 days prior to enrollment their last dose of biological therapy such as biological response modifiers e . g . cytokines immunomodulatory agents vaccines differentiating agents used to treat their cancer at least 28 days prior to enrollment their last dose of a monoclonal antibody at least 28 days prior to enrollment and their last dose of any investigational agent at least 28 days prior to enrollment participants must have recovered from the acute toxic effects of prior therapy to a grade 1 common terminology criteria for adverse events ctcae v . 4 . 0 level prior to enrollment does not apply to alopecia                                                                                                          ",1
"300","patients must have fully recovered from the acute toxic effects of all prior chemotherapy immunotherapy or radiotherapy prior to entering this study myelosuppressive anti cancer",1,"and the target cutaneous neurofibromas have to be in areas outside of a prior radiation field                                                                                                                                                                                                                                                             ",1
"301","have received surgery chemotherapy and / or radiation",1,"xrt small port > = 6 weeks must have elapsed since treatment with therapeutic doses of m iodobenzylguanidine mibg > = 3 months must have elapsed if prior craniospinal xrt was received if > = 50 of the pelvis was irradiated or if total body irradiation tbi was received > = 6 weeks must have elapsed if other substantial bone marrow irradiation was given subjects should not have any clinically relevant ongoing complications from prior radiation therapy i . e . radiation esophagitis or other inflammation of the viscera                                                                                                                                                                                          ",1
"302","have completed all surgery chemotherapy and / or radiation",1,"chemotherapy or radiation                                                                                                                                                                                                                                                                                 ",1
"304","at least 2 weeks from end of radiation",1,"with curative intent                                                                                                                                                                                                                                                                               ",1
"305","no prior pelvic radiation",1,"chemotherapy radiation while on study                                                                                                                                                                                                                                                                               ",1
"307","all women who undergo breast conserving",1,"for optimal management prior to surgical resection                                                                                                                                                                                                                                                               ",1
"314","> = 2 weeks must have elapsed since local palliative radiation",1,"rt to the affected breast or chest wall and regional nodal areas is clinically indicated as per nccn treatment guidelines should receive rt after randomization when possible and receive mk 3475 pembrolizumab concurrent with rt if randomized to the experimental arm however rt administered or initiated prior to registration is also allowed pembrolizumab may be added to ongoing radiation or started after its completion if randomized to the experimental arm provided there are no > = grade 2 radiation related skin toxicities patients who have not yet started radiation must specify at the time of screening registration whether or not they will receive rt and the extent of intended rt                                                                                                                                                                            ",1
"315","at least 21 days must have elapsed from prior systemic",1,"in the affected breast                                                                                                                                                                                                                                                                                   ",1
"316","disease that is currently not amenable to surgery radiation or combined modality",1,"and temozolomide according to the response assessment in neuro oncology rano criteria with new contrast enhancing lesion outside of radiation field on decreasing stable or increasing doses of corticosteroids increase by > = 25 in the sum of the products of perpendicular diameters between the postradiotherapy scan with the smallest tumor measurement and a scan at least 12 weeks from completion of radiation therapy rt temozolomide tmz on stable or increasing doses of corticosteroids note clinical deterioration not attributable to concurrent medication or comorbid conditions is sufficient to declare progression on current treatment but not for entry onto a clinical trial for recurrence                                                                                                                                                                          ",1
"317","no other planned concurrent investigational agents or other tumor directed",1,"and temozolomide                                                                                                                                                                                                                                                                                  ",1
"318","patients must have a primary tumor that are determined by multidisciplinary team medical oncology orthopedic / surgical oncology and radiation oncology to require radiation",1,"planning and must be 30 days prior to the start of radiation therapy enrolling sites are not mandated although highly encouraged to obtain thin slice < 1 . 5 mm 3 dimensional d axial t2 / flair and t1 pre and post contrast sequences for planning purposes                                                                                                                                                                                                                                    ",1
"319","patients for whom radiation",1,"will be used on this protocol                                                                                                                                                                                                                                                                              ",1
"320","patients with any history of prior radiation",1,"",NA
"321","patients must have histologically confirmed glioblastoma that is progressive or recurrent following radiation",1,"",NA
"322","patients must be in first recurrence of glioblastoma following radiation",1,"",NA
"323","post operative mri imaging with contrast is mandatory obtained for radiation",1,"",NA
"324","planned use of cytotoxic chemotherapy during radiation only adjuvant temozolomide",1,"",NA
